Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Rectal Cancer

Rectal Cancer

105

Pipeline Programs↗

194

Active Trials↗

40

Companies Involved↗

Rectal Cancer is a highly competitive landscape with 105 programs across 40 companies. The most active players are DynamiCure Biotechnology. 34 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

79/100

Pipeline Velocity

73/100

Mech. Concentration

19/100

Completion Rate

75/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

DynamiCure Biotechnology

1 program

Pipeline

Programs by Phase

Preclinical8

HA35

Nakhia Impex LLC

Total Neoadjuvant Therapy

St. James's Hospital, Ireland

Raltitrexed

Nanjing Chia-tai Tianqing Pharmaceutical

Therapeutic Target Tailored Chemotherapy

Grupo Hospital de Madrid

Adjuvant Chemotherapy

Nizhny Novgorod Regional Clinical Oncology Center

Phase 17

PD-1 Blocking Antibody

Sun Yat-sen University

Consolidation Therapy

Institute of Hematology & Blood Diseases Hospital, China

Papaverine

Western Galilee Hospital-Nahariya

Copper Cu-64-DOTA-Alendronate

City of Hope Medical Center

Imfinzi

University Medical Center Groningen

Phase 256

Liposomal Irinotecan

Astellas

DCSZ11

DynamiCure Biotechnology

Etrumadenant

Arcus Biosciences

Zimberelimab

Arcus Biosciences

Ivonescimab

Summit Therapeutics

Phase 334

Leucovorin

Glaxo Dba Glaxosmithkline

PD-1 Antibody

Sir Run Run Shaw Hospital

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Oxaliplatin

Teva

PD-1

Sichuan Baili Pharmaceutical Co., Ltd.

Approved

No programs

Analysis

Modality Breakdown

71%

Small molecule

67 of 94 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 94 classified programs, each share of the total. Modality classified for 92% of 105 pipeline programs.

Analysis

Trial Status

409

clinical trials

Completed116 · 28%

Recruiting97 · 24%

Unknown status60 · 15%

Not yet recruiting50 · 12%

Active, not recruiting46 · 11%

Terminated25 · 6%

Other15 · 4%

Clinical Trials

Trial Activity

409 trials

Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer

Recruiting·OOHSU Knight Cancer Institute·N/A·NCT05081024·50 enrolled

Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node, a Prospective, Multicenter, Non-inferior Randomized Controlled Trial

Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·Preclinical·NCT06146946·1,384 enrolled

A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04165772·212 enrolled

Clinical Study Evaluating the Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)

Recruiting·IInstitut du Cancer de Montpellier - Val d'Aurelle·Preclinical·NCT07098182·50 enrolled

A Prospective Single-Arm Phase II Study of Pelvic External Beam Radiotherapy Followed by HDR Endorectal Brachytherapy Combined With a 3D-Printed Individualized Guide Template and Tungsten-Alloy Local Shielding for Organ Preservation in Inoperable Localized Rectal Cancer

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Preclinical·NCT07786493·50 enrolled

The PRELUDE Study: A Prospective Cohort Study Comparing Neoadjuvant Radiotherapy Followed by Total Mesorectal Excision Versus Upfront Surgery in Patients With Locally Advanced Proximal Rectal Cancer

Recruiting·IIstanbul University·Preclinical·NCT07802197·100 enrolled

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT07292298·44 enrolled

Prospective Evaluation of Quality of Life and Utilities Following Surgical Treatment of Rectal Cancer

Recruiting·MM.D. Anderson Cancer Center·N/A·NCT02107105·430 enrolled

Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial

Recruiting·LLarissa University Hospital·Preclinical·NCT05496491·84 enrolled

A Randomized Phase 2 Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With and Without BMX-001 as Part of Total Neoadjuvant Therapy in Patients With Newly Diagnosed Locally Advanced Rectal Adenocarcinoma

Recruiting·UUniversity of Nebraska·Phase 2·NCT05254327·118 enrolled

Identification of Tissue Biomarkers for Predicting Neoadjuvant Chemoradio-resistance in Patients With Middle-low Local Advanced Rectal Cancer.

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT03573791·152 enrolled

Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT): A Prospective Randomized Swedish Phase II Trial

Recruiting·—·Preclinical·NCT04525989·254 enrolled

Contact Radiotherapy for Rectal Cancer (CORRECT): a Multicenter Randomized Phase II Trial

Recruiting·—·Preclinical·NCT06501053·110 enrolled

Short-Course Radiotherapy Followed by Ivonescimab (AK112) in pMMR/MSS Mid-Low Rectal Cancer: An Exploratory Phase II Clinical Study.

Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT07162714·30 enrolled

Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Recruiting·XXijing Hospital·Phase 2·NCT07750951·34 enrolled

Page 1 of 28

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)